Litfulo is NOT contraindicated in patients with a history of prostate cancer post-prostatectomy
Based on the FDA prescribing information, Litfulo (ritlecitinib) has only one contraindication: known hypersensitivity to ritlecitinib or any of its excipients—a history of prostate cancer is not listed as a contraindication 1.
Key Considerations for Use
What the FDA Label Actually Says
The boxed warning for Litfulo focuses on:
- Serious infections (including tuberculosis)
- Mortality risks observed with other JAK inhibitors in rheumatoid arthritis patients
- Malignancies (including lymphomas and lung cancers seen with other JAK inhibitors)
- Major adverse cardiovascular events
- Thrombosis
Importantly, the malignancy warning is based on data from other JAK inhibitors used in rheumatoid arthritis patients, not from the alopecia areata population for which Litfulo is approved 1.
Safety Data in the Actual Patient Population
The integrated safety analysis from the ALLEGRO trials (n=1,294 patients, median exposure 624 days) showed:
- Malignancies (excluding non-melanoma skin cancer): 0.5% of patients (0.3/100 patient-years)
- Two deaths total: one from breast cancer, one from acute respiratory failure
- No specific signal for prostate cancer 2
Clinical Decision Framework
When to Use Litfulo in This Population
You can prescribe Litfulo to a patient with prior prostate cancer post-prostatectomy if:
- The prostate cancer has been definitively treated (which prostatectomy accomplishes)
- There is no evidence of active/recurrent disease (undetectable PSA, no metastases)
- The patient has severe alopecia areata (the approved indication)
- The benefits outweigh the theoretical malignancy risk from JAK inhibition
Monitoring Strategy
For patients with prior prostate cancer:
- Continue standard post-prostatectomy PSA surveillance (typically every 3-6 months initially, then annually)
- Perform baseline absolute lymphocyte count and platelet count before starting 1
- Monitor for signs of infection given immunosuppressive effects
- Screen for tuberculosis before initiation 1
Critical Pitfall to Avoid
Do not confuse "boxed warning about malignancy" with "contraindication for patients with prior cancer." The boxed warning is a general caution about JAK inhibitor class effects observed in a different disease population (RA patients), not a prohibition against use in cancer survivors. The FDA explicitly lists only hypersensitivity as a contraindication 1.
The Evidence Gap
The provided prostate cancer survivorship guidelines 3 address post-treatment sexual function and bone health but do not discuss JAK inhibitors or immunomodulatory therapy restrictions. This absence of specific guidance reflects that there is no established contraindication for using immunomodulators in patients with successfully treated, non-active prostate cancer.
The decision should weigh the severity of the alopecia areata (which can significantly impact quality of life) against the theoretical increased malignancy risk from JAK inhibition in someone with a prior cancer history. Given that prostatectomy is curative for localized disease and the patient would be under PSA surveillance regardless, Litfulo can be used with appropriate informed consent and monitoring.